Dyne Therapeutics, Inc. Increase (Decrease) in Accounts Payable and Other Operating Liabilities
Dyne Therapeutics, Inc. (DYN) reported Increase (Decrease) in Accounts Payable and Other Operating Liabilities of $14.16 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities · last filed 2026-07-29
- Dyne Therapeutics, Inc. increase (decrease) in accounts payable and other operating liabilities for the quarter ending 2026-06-30 was $18.96M, a 141.72% increase year-over-year.
- Dyne Therapeutics, Inc. increase (decrease) in accounts payable and other operating liabilities for the quarter ending 2026-03-31 was -$4.80M.
- Dyne Therapeutics, Inc. increase (decrease) in accounts payable and other operating liabilities for the quarter ending 2025-12-31 was -$9.46M.
- Dyne Therapeutics, Inc. increase (decrease) in accounts payable and other operating liabilities for the quarter ending 2025-09-30 was $18.47M, a 37.69% increase year-over-year.
- Dyne Therapeutics, Inc. increase (decrease) in accounts payable and other operating liabilities for fiscal 2025 was $8.25M.
- Dyne Therapeutics, Inc. increase (decrease) in accounts payable and other operating liabilities for fiscal 2024 was -$8.96M, a 138.99% decline from fiscal 2023.
- Dyne Therapeutics, Inc. increase (decrease) in accounts payable and other operating liabilities for fiscal 2023 was $22.97M.
- Dyne Therapeutics, Inc. increase (decrease) in accounts payable and other operating liabilities for fiscal 2022 was -$1.24M, a 109.01% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable and Other Operating Liabilities 3 month | Increase (Decrease) in Accounts Payable and Other Operating Liabilities 6 month | Increase (Decrease) in Accounts Payable and Other Operating Liabilities 9 month | Increase (Decrease) in Accounts Payable and Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $18.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $14.16M 10-Q · filed 2026-07-29 | $4.70M derived: sum of 3 quarters · filed 2026-07-29 | $23.17M derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | -$4.80M 10-Q · filed 2026-05-11 | -$14.27M derived: sum of 2 quarters · filed 2026-05-11 | $4.20M derived: sum of 3 quarters · filed 2026-05-11 | $12.05M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | -$9.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $9.01M derived: sum of 2 quarters · filed 2026-03-02 | $16.85M derived: sum of 3 quarters · filed 2026-07-29 | $8.25M 10-K · filed 2026-03-02 |
| 2025-09-30 | $18.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $26.32M derived: sum of 2 quarters · filed 2026-07-29 | $17.71M 10-Q · filed 2025-11-05 | $16.72M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | $7.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | -$756.00K 10-Q · filed 2026-07-29 | -$1.75M derived: sum of 3 quarters · filed 2026-07-29 | $11.67M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-03-31 | -$8.60M 10-Q · filed 2026-05-11 | -$9.59M derived: sum of 2 quarters · filed 2026-05-11 | $3.82M derived: sum of 3 quarters · filed 2026-05-11 | $11.20M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$991.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $12.42M derived: sum of 2 quarters · filed 2026-03-02 | $19.80M derived: sum of 3 quarters · filed 2026-03-02 | -$8.96M 10-K · filed 2026-03-02 |
| 2024-09-30 | $13.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $20.79M derived: sum of 2 quarters · filed 2025-11-05 | -$7.96M 10-Q · filed 2025-11-05 | $13.45M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $7.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-28 | -$21.38M 10-Q · filed 2025-07-28 | $33.00K derived: sum of 3 quarters · filed 2026-03-02 | $9.49M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | -$28.76M 10-Q · filed 2025-05-08 | -$7.35M derived: sum of 2 quarters · filed 2026-03-02 | $2.11M derived: sum of 3 quarters · filed 2026-03-02 | $743.00K derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $21.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $30.87M derived: sum of 2 quarters · filed 2026-03-02 | $29.50M derived: sum of 3 quarters · filed 2026-03-02 | $22.97M 10-K · filed 2026-03-02 |
| 2023-09-30 | $9.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $8.09M derived: sum of 2 quarters · filed 2024-11-12 | $1.56M 10-Q · filed 2024-11-12 | $6.21M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | -$1.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$7.90M 10-Q · filed 2024-08-12 | -$3.25M derived: sum of 3 quarters · filed 2025-02-27 | -$4.41M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$6.53M 10-Q · filed 2024-05-02 | -$1.89M derived: sum of 2 quarters · filed 2025-02-27 | -$3.04M derived: sum of 3 quarters · filed 2025-02-27 | -$1.50M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $4.65M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $3.49M derived: sum of 2 quarters · filed 2025-02-27 | $5.03M derived: sum of 3 quarters · filed 2025-02-27 | -$1.24M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$1.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-30 | $387.00K derived: sum of 2 quarters · filed 2023-10-30 | -$5.88M 10-Q · filed 2023-10-30 | $146.00K derived: sum of 4 quarters · filed 2023-10-30 |
| 2022-06-30 | $1.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$4.72M 10-Q · filed 2023-08-03 | $1.30M derived: sum of 3 quarters · filed 2023-08-03 | $6.14M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | -$6.27M 10-Q · filed 2023-05-11 | -$241.00K derived: sum of 2 quarters · filed 2023-05-11 | $4.59M derived: sum of 3 quarters · filed 2023-05-11 | $5.57M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $6.03M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $10.86M derived: sum of 2 quarters · filed 2023-03-02 | $11.83M derived: sum of 3 quarters · filed 2023-03-02 | $13.70M 10-K · filed 2023-03-02 |
| 2021-09-30 | $4.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $5.81M derived: sum of 2 quarters · filed 2022-11-03 | $7.67M 10-Q · filed 2022-11-03 | $15.13M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $973.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $2.84M 10-Q · filed 2022-08-04 | $10.29M derived: sum of 3 quarters · filed 2022-08-04 | $9.69M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $1.87M 10-Q · filed 2022-05-02 | $9.32M derived: sum of 2 quarters · filed 2022-05-02 | $8.71M derived: sum of 3 quarters · filed 2022-05-02 | $9.94M derived: sum of 4 quarters · filed 2022-05-02 |
| 2020-12-31 | $7.45M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $6.84M derived: sum of 2 quarters · filed 2022-03-10 | $8.07M derived: sum of 3 quarters · filed 2022-03-10 | $8.57M 10-K · filed 2022-03-10 |
| 2020-09-30 | -$608.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $613.00K derived: sum of 2 quarters · filed 2021-11-04 | $1.11M 10-Q · filed 2021-11-04 | $2.30M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $1.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $1.72M 10-Q · filed 2021-08-05 | $2.91M derived: sum of 3 quarters · filed 2021-08-05 | |
| 2020-03-31 | $501.00K 10-Q · filed 2021-05-06 | $1.69M derived: sum of 2 quarters · filed 2021-05-06 | ||
| 2019-12-31 | $1.18M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | $1.69M 10-K · filed 2021-03-04 | ||
| 2019-09-30 | $505.00K 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |